| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AADAT |
| Uniprot No | Q8N5Z0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-425aa |
| 氨基酸序列 | PKSMISLAGGLPNPNMFPFKTAVITVENGKTIQFGEEMMKRALQYSPSAGIPELLSWLKQLQIKLHNPPTIHYPPSQGQMDLCVTSGSQQGLCKVFEMIINPGDNVLLDEPAYSGTLQSLHPLGCNIINVASDESGIVPDSLRDILSRWKPEDAKNPQKNTPKFLYTVPNGNNPTGNSLTSERKKEIYELARKYDFLIIEDDPYYFLQFNKFRVPTFLSMDVDGRVIRADSFSKIISSGLRIGFLTGPKPLIERVILHIQVSTLHPSTFNQLMISQLLHEWGEEGFMAHVDRVIDFYSNQKDAILAAADKWLTGLAEWHVPAAGMFLWIKVKGINDVKELIEEKAVKMGVLMLPGNAFYVDSSAPSPYLRASFSSASPEQMDVAFQVLAQLIKESL |
| 预测分子量 | 60.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AADAT(氨基己二酸氨基转移酶)重组蛋白研究的假设性参考文献示例(注：实际文献需通过学术数据库验证)：
---
1. **文献名称**: *Expression and Purification of Recombinant Human AADAT for Functional Studies*
**作者**: Han, Q. et al.
**摘要**: 报道了在大肠杆菌中高效表达人源AADAT重组蛋白的优化方法，通过亲和层析纯化获得高活性蛋白，并验证其在犬尿氨酸途径中的酶催化功能。
2. **文献名称**: *Structural Insights into AADAT via Crystallography*
**作者**: Suzuki, M. et al.
**摘要**: 利用重组AADAT蛋白进行X射线晶体学分析，解析了其三维结构，揭示了底物结合口袋的关键氨基酸残基，为酶机制研究提供依据。
3. **文献名称**: *AADAT Dysregulation in Alzheimer's Disease Models*
**作者**: Ishii, T. et al.
**摘要**: 通过重组AADAT处理神经元细胞，发现其代谢产物异常积累与β-淀粉样蛋白毒性相关，提示AADAT在阿尔茨海默病病理中的作用。
4. **文献名称**: *High-Throughput Screening of AADAT Inhibitors*
**作者**: Zhang, Y. et al.
**摘要**: 建立基于重组AADAT蛋白的体外筛选平台，发现小分子抑制剂可调节犬尿氨酸代谢，为治疗神经炎症提供潜在药物靶点。
---
建议通过 **PubMed** 或 **Web of Science** 搜索关键词 "AADAT recombinant protein" 或 "kynurenine aminotransferase expression" 获取真实文献。
**Background of AADAT Recombinant Protein**
Aminoadipate aminotransferase (AADAT), also known as kynurenine aminotransferase II (KAT II), is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that plays a critical role in cellular metabolism. It catalyzes the transamination of α-aminoadipic acid (α-AAA) to α-ketoadipate in the lysine degradation pathway and is involved in the conversion of kynurenine to kynurenic acid (KYNA) within the tryptophan-kynurenine pathway. KYNA, a neuroactive metabolite, acts as an endogenous antagonist of glutamate receptors (NMDAR) and α7-nicotinic acetylcholine receptors, influencing neurotransmission and neuroprotection. Dysregulation of AADAT activity or KYNA levels has been implicated in neurological disorders such as schizophrenia, Alzheimer’s disease, and epilepsy.
Recombinant AADAT protein is produced via heterologous expression systems (e.g., *E. coli*, yeast, or mammalian cells*) to enable high-purity, scalable yields for functional and structural studies. Its production facilitates research into enzyme kinetics, substrate specificity, and inhibitor screening, particularly for therapeutic targeting. For instance, modulating AADAT/KAT II activity could adjust KYNA levels, offering potential therapeutic strategies for CNS disorders. Structural analyses (e.g., X-ray crystallography) of recombinant AADAT have revealed insights into its active-site architecture and PLP-cofactor interactions, guiding drug design.
Overall, recombinant AADAT serves as a vital tool for unraveling its biological roles, developing diagnostics, and advancing therapies for metabolic and neurological diseases.
×
